Cargando…
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
Raltegravir is the first licensed compound in 2007 of the new integrase inhibitor drug class. At the dose of 400 mg twice daily, raltegravir showed a potent antiviral action in antiretroviral-naïve patients when associated with tenofovir and emtricitabine. Raltegravir was also found to be highly act...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108740/ https://www.ncbi.nlm.nih.gov/pubmed/21694899 http://dx.doi.org/10.2147/IDR.S8673 |